Top

BioDrugs

Published in:

01-05-2004 | Adis Drug Profile

Etanercept

In Ankylosing Spondylitis

Authors: Paul L. McCormack, Keri Wellington

Published in: BioDrugs | Issue 3/2004

Abstract

▴ Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNFα and blocks its biological activity.

▴ Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid arthritis. More recently, etanercept has shown efficacy in the treatment of adults with ankylosing spondylitis.

▴ In randomized, double-blind, placebo-controlled trials, subcutaneous etanercept 25mg twice weekly for 6–24 weeks significantly reduced disease activity in patients with active ankylosing spondylitis. In the largest trial, etanercept produced a response rate of 57% compared with 22% for placebo after 24 weeks (response was determined via the validated ASAS 20 response criteria developed by the Assessments in Ankylosing Spondylitis [ASAS] Working Group).

▴ Etanercept therapy significantly improved health-related quality of life in patients with ankylosing spondylitis compared with placebo. The greatest improvements in a 16-week study were seen in the domains of physical functioning, physical role, bodily pain, vitality, and social functioning.

▴ Etanercept was generally well tolerated, with few serious adverse events or treatment withdrawals. The most common adverse events were injection-site reactions and minor upper respiratory tract infections.

The use of trade names is for product identification purposes only and does not imply endorsement.

Immunex Corporation. ENBREL® (etanercept): US prescribing information [online]. Available from URL: http://www.wyeth.com [Accessed 2004 Jan 16]

Reimold AM. TNFα as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 2002 Dec; 1(4): 377–92PubMedCrossRef

Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 2003 Aug; 33(1): 1–18PubMedCrossRef

Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002; 62(17): 2493–537PubMedCrossRef

Sieper J, Braun J. Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opin Emerg Drugs 2002; 7(2): 235–46PubMedCrossRef

Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61Suppl. III: iii8–iii18PubMed

Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66PubMedCrossRef

Zou J, Rudwaleit M, Brandt J, et al. Up regulation of the production of tumour necrosis factor a and interferon y by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003 Jun; 62(6): 561–4PubMedCrossRef

Zou J, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48(3): 780–90PubMedCrossRef

10.

Davis JC, Webb A, Buenviaje H, et al. Etanercept suppresses serological markers of articular cartilage degradation/turnover in patients with ankylosing spondylitis [abstract no. FRI0152]. Ann Rheum Dis 2003 Jul; 62Suppl. 1: 242

11.

Zhou H, Buckwalter M, Boni J, et al. Pharmacokinetics (PK) of etanercept in ankylosing spondylitis (AS) patients: a population-based investigation [abstract no. 82]. J Clin Pharmacol 2003 Sep; 43(9): 1033

12.

Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50(2): 353–63PubMedCrossRef

13.

Lebsack ME, Hanna RK, Lange MA, et al. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers [abstract no. 233]. Pharmacotherapy 1997; 17(5): 1118–9

14.

European Agency for the Evaluation of Medicinal Products. Enebrel [online]. Available from URL: http://www.emea.eu.int [Accessed 2004 Mar 8]

15.

Korth-Bradley JM, Parks V, Buckwalter ME, et al. Lack of a clinically relevant interaction between etanercept and warfarin. Pharmacotherapy 2002; 22(3): 420. Plus poster presented at the American College of Clinical Pharmacy Spring Practice and Research Forum; 2002 Apr 7–10; Savannah (GA)

16.

Patat AA, Parks V, Simcoe DK, et al. Lack of a clinically relevant interaction between etanercept (E) & digoxin (D) [abstract no. TPII-82]. Clin Pharmacol Ther 2002; 71(2): 64. Plus poster presented at the 103rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2002 Mar 24–27; Atlanta (GA)

17.

Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003 Jun; 48(6): 1667–75PubMedCrossRef

18.

Calin A, Dijkmans B, Emery P, et al. A multicentre, placebo-controlled trial of Enbrel in ankylosing spondylitis [abstract no. OP0097]. Ann Rheum Dis 2003 Jul; 62Suppl. 1:95

19.

Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med 2002 May 2; 346(18): 1349–56PubMedCrossRef

20.

Davis Jr JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003 Nov; 48(11): 3230–6PubMedCrossRef

21.

Calin A, Dijkmans B, Emery P, et al. Assessments of disease activity and functionality in Enbrel-treated patients with ankylosing spondylitis in a multi-center, placebo-controlled trial [poster no. 350]. American College of Rheumatology 67th Annual Scientific Meeting; 2003 Oct 23–28; Orlando (FL)

22.

Immunex Corporation. Etanercept for the treatment of ankylosing spondylitis: Advisory Committee meeting clinical review briefing document [online]. Available from URL: http://www.fda.gov [Accessed 2004 Mar 15]

23.

Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 Aug; 44(8): 1876–86PubMedCrossRef

24.

van der Heijde D, Calin A, Dougados M, et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis: progress report of the ASAS Working Group. J Rheu-matol 1999; 26: 951–4

25.

Davis Jr JC. The role of etanercept in ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S111–5PubMed

26.

Davis Jr J, Webb A, Lund S, et al. Results from an open-label extension study of etanercept in ankylosing spondylitis [letter]. Arthritis Care Res 2004; 51(2): 302–4CrossRef

27.

Davis JC, Woolley JM. Improvements in patient-reported outcomes for subjects with ankylosing spondylitis receiving etanercept therapy [abstract no. FRI0184]. Ann Rheum Dis 2003 Jul; 62Suppl. 1: 252

28.

Boonen A, Severens JL, van der Heijde D, et al. Markov model into the cost-utility over 5 years of TNF-α inhibitors compared to usual care in patients with active ankylosing spondylitis [abstract no. 601]. Arthritis Rheum 2003 Sep; 48 (9 Suppl.): S264–5

29.

Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003 Feb; 29(1): 185–202PubMedCrossRef

30.

Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol 2002 Sep; 29Suppl. 65: 33–8

31.

Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003 Mar; 3(3): 148–55PubMedCrossRef

32.

Long R, Gardam M. Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003 Apr 29; 168(9): 1153–6PubMed

33.

Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002 Dec; 46(12): 3151–8PubMedCrossRef

34.

Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S152–7PubMed

35.

Wyeth Europa Ltd. Enbrel® (etanercept). Summary of Product Characteristics. Taplow, Maidenhead (Berkshire), UK: Wyeth Europa Ltd, 2004 Jan 16

Title: Etanercept
In Ankylosing Spondylitis
Authors: Paul L. McCormack
Keri Wellington
Publication date: 01-05-2004
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 3/2004
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200418030-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Etanercept

In Ankylosing Spondylitis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2004

Is There a Future for Neural Transplantation?

Development of a Reproducible Procedure for Plasmid DNA Encapsulation by Red Blood Cell Ghosts

Etanercept

Electroporation for Gene Transfer to Skeletal Muscles

Etanercept

Kinase Targets and Inhibitors for the Treatment of Airway Inflammatory Diseases